Introduction
============

Long-term adherence to antiretroviral therapy (ART) is critical for achieving optimal clinical outcomes among people living with HIV, as well as reducing the risk of transmission to uninfected partners.[@b1-clep-10-017]--[@b4-clep-10-017] Regimen complexity, characterized by multiple pills, differing dosing times, as well as varying dosing instructions have been shown to be important factors contributing to suboptimal adherence.[@b5-clep-10-017],[@b6-clep-10-017] In turn, people with poor adherence have been identified to be at an increased risk for incomplete virologic suppression, development of drug resistance, disease progression, and death.[@b7-clep-10-017],[@b8-clep-10-017]

While regimen complexity has been noted as a barrier to adherence, the introduction of fixed-dose combinations (FDCs) where one pill contains multiple active drugs has simplified pill taking. This is achieved through a reduction in pill burden in combination with simpler scheduling (once daily).[@b9-clep-10-017] Introduced to resource-limited settings in the early 2000s, FDCs were initially a combination of two active antiretroviral (ARV) drugs administered as one pill (e.g., Truvada®; Gilead Sciences, Inc., Foster City, CA, USA; emtricitabine (FTC) and tenofovir disoproxil fumarate \[TDF\]).[@b9-clep-10-017] Although not in widespread use at the onset, numerous clinical trials and observational cohort studies report improved patient satisfaction, quality of life, adherence and virologic suppression through these simplified regimens (both two and three active drugs administered in a FDC).[@b10-clep-10-017]--[@b12-clep-10-017] While the immunologic and virologic effects of FDCs appear positive, there is still limited data on the effects of FDCs administered to individuals at scale, under routine clinical conditions.[@b4-clep-10-017]

In April 2013, South Africa began initiating eligible first-line patients on a once-daily, single-tablet FDC ARV regimen of TDF, FTC, and efavirenz (EFV).[@b13-clep-10-017] To evaluate the impact of this policy change, we compared treatment outcomes among patients who initiated this FDC ARV regimen ≥5 months after FDCs became available, to patients who initiated a TDF, lamivudine (3TC), and EFV multi-pill ART regimen prior to FDC introduction at a large public sector HIV clinic in Johannesburg, South Africa.

Methods
=======

Study design, site, and population
----------------------------------

We conducted a retrospective cohort study of non-pregnant, non-tuberculosis (TB) patients initiating first-line ART at Themba Lethu Clinic, located at Helen Joseph Hospital in Johannesburg, South Africa.

At Themba Lethu, demographic, laboratory, and clinical data were captured on an electronic patient management system called TherapyEdge-HIV™ (Advanced Biological Laboratories, SA, Luxembourg).[@b14-clep-10-017] HIV care and treatment at Themba Lethu followed the South African ART Guidelines.[@b15-clep-10-017]--[@b19-clep-10-017] After treatment initiation, patients were typically scheduled for medical follow-up visits at 1, 3, 6, and 12 months and then 6-monthly thereafter.[@b16-clep-10-017],[@b20-clep-10-017] During the study period, ART eligibility was based on a CD4 cell count ≤350 cells/mm^3^.[@b17-clep-10-017],[@b18-clep-10-017] Since the implementation of the 2010 national treatment guidelines, monitoring laboratory tests such as viral load tests are performed at 6 and 12 months post-initiation, and annually thereafter. Additionally, CD4 cell count tests are performed 12 months following ART initiation, and annually thereafter. Complete blood counts, hemoglobin, creatinine clearance, and liver function tests are performed at least annually.

Study population
----------------

The study population consisted of HIV-positive non-pregnant, non-TB, ART-naïve adults (≥18 years) initiating a triple combination, TDF-based regimen. We compare two groups: an unexposed multi-pill group who initiated TDF/3TC/EFV with 3--5 pills per day between September 1, 2011 and August 31, 2012, prior to the introduction of FDCs; and an exposed group who initiated a single-pill per day regimen (TDF/FTC/EFV) from September 1, 2013 to August 31, 2014, ≥5 months after the introduction of FDCs to allow for the clinic to transition and implement the policy change. Both groups were followed-up until 12 months post-ART initiation.

Study variables
---------------

We compared the multi-pill and FDC groups with respect to the following outcomes: 1) attrition (a combination of lost to follow-up \[LTFU\], defined as being \>3 months late for the last scheduled visit with no subsequent visit and all-cause mortality/death, determined by family and/or hospital report as well as linkage to the South African National Vital Registration System in August 2014 for patients with a valid South African national identification number;[@b21-clep-10-017],[@b22-clep-10-017] 2) missing a medical visit (0 vs ≥1) defined as being \>7 days late for a scheduled medical visit;[@b23-clep-10-017] and 3) virologic suppression defined as a viral load \<400 copies/mL at 6 and 12 months post-ART initiation (+/−3 months). Due to the relatively small number of patients having experienced LTFU or mortality across respective regimen types by 12 months, these outcomes were not assessed separately; instead LTFU and mortality were combined into attrition by 12 months (LTFU + all-cause mortality). For primary outcomes, person-time accrued from ART initiation to the earliest of: 1) attrition; 2) transfer out to another facility; 3) completed 12 months of follow-up, and when reporting total follow-up time, to the close of dataset (April 5, 2016).

Statistical analysis
--------------------

Baseline demographic and clinical characteristics of all patients included in the cohorts were presented using medians with corresponding interquartile ranges (IQRs) for continuous variables, while categorical variables were presented as simple proportions along with a count of missing data. Primary outcomes were assessed using complete case analysis. Attrition and missed visits were measured by 12 months post-ART initiation, while virologic suppression was measured at both 6 and 12 months post-ART initiation (+/−3 months). Due to the variation in time to outcome (LTFU/mortality), Cox proportional hazards models were used to evaluate the relationship between FDCs vs multiple pills and attrition. Poisson regression was used to estimate the association between FDCs vs multiple pills for both missed medical visits and virologic suppression. Proportions and relative rates (RRs) of virologic suppression were calculated among only those with viral load tests at respective time points. Additionally, we conducted a sensitivity analysis to identify the impact of missing data. At both time points of viral load measurement, patients alive and in care with missing viral load tests were categorized as having suppressed and unsuppressed viral loads in two respective Poisson regression models. All baseline characteristics which resulted in a ≥±10% change in the primary exposure effect were included in the respective adjusted models. Additionally, potential confounders known through prior knowledge or hypothesized to be associated with respective outcomes were included in the adjusted models. Demographic and clinical characteristics considered a priori included; age, sex, CD4 cell count, and World Health Organization (WHO) stage (according to national guidelines, CD4 cell count and WHO stage are characteristics which determine ART initiation across regimen types and were consequently considered as a priori). Due to the setting of the clinic site (high altitude), hemoglobin levels were first adjusted down by 0.65 g/dL, and defined per sex for males as 1) no anemia (Hb ≥13 g/dL), 2) mild anemia (10\< Hb \<13 g/dL), 3) moderate anemia (8≤ Hb ≤10 g/dL), and 4) severe anemia (Hb \<8 g/dL); and for females as 1) no anemia (Hb ≥12 g/dL), 2) mild anemia (10\< Hb \<12 g/dL), 3) moderate anemia (8≤ Hb ≤10 g/dL), and 4) severe anemia (Hb \<8 g/dL).

Ethical approval
----------------

Ethical approval for the use of data was provided by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M140201). The study protocol was reviewed by the Institutional Review Board of the University of the Witwatersrand who approved the collection of the data without informed consent and the use of an anonymous analytical data set.

Results
=======

Demographic and clinical characteristics
----------------------------------------

We included 3151 patients in our analysis. Overall, 2230 (70.8%) patients initiated multi-pill ART (September 1, 2011--August 31, 2012) and 921 (29.2%) patients initiated on a FDC (September 1, 2013--August 31, 2014). [Table 1](#t1-clep-10-017){ref-type="table"} presents the demographic and clinical characteristics of patients on each regimen type at initiation. The proportion of females was similar between patients taking multiple pills and those on FDCs (61.1 vs 54.3%) as was the median age at initiation (37.8 years for both groups) and median hemoglobin at initiation (11.7 vs 11.9 g/dL). Patients on a multi-pill regimen presented a marginally higher median CD4 cell count at ART initiation compared to those on a FDC (175.5 vs 158.0 cells/mm^3^), while a lower proportion of the former initiated with CD4 cell counts \>350 cells/mm^3^ (4.3 vs 10.8%). Levels of creatinine clearance, body mass index (BMI), and WHO clinical stage were similar across groups. By 12 months post-ART initiation, more than 75% of patients were still alive in care. Lost to follow-up, mortality, and transfer-out were 12, 6, and 7%, respectively. Overall, 16% of patients missed one or more medical visits by 12 months on ART, while more than 75% of patients suppressed their viral load by 6 and 12 months, respectively.

Attrition by 12 months on ART
-----------------------------

By 12 months on ART, the overall incidence of attrition was 17.5% (552/3151) (11.9% were LTFU and 5.6% had died). The attrition rate within the first year of ART was 20.3/100 person-years. This was lower among those on FDCs (17.6/100 person-years) compared to those taking multiple pills (21.5/100 person-years). [Table 2](#t2-clep-10-017){ref-type="table"} shows the crude hazard ratio (HR) and adjusted HR (aHR) estimates of attrition by 12 months post-ART initiation. While those on FDCs had a reduced risk of attrition in crude analyses (HR: 0.82; 95% CI: 0.68--1.00), aHRs reveal that patients on FDCs have approximately the same risk of attrition by 12 months compared to those on multi-pills (aHR: 0.98; 95% CI: 0.77--1.24). Males (aHR: 1.49; 95% CI: 1.17--1.90), those with a lower CD4 cell count (0--50 vs ≥201 cells/mm^3^, aHR: 2.29; 95% CI: 1.69--3.12 and 51--100 vs ≥201 cells/mm^3^, aHR: 1.48; 95% CI: 1.01--2.16), patients with advanced anemia (moderate vs none, aHR: 1.71; 95% CI: 1.22--2.39) and (severe vs none, aHR: 2.42; 95% CI: 1.56--3.75), as well as those with low BMI (\<18.5 vs 18.5--24.9 kg/m^2^, aHR: 1.42; 95% CI: 1.07--1.87) were more likely to be lost from care or die. In contrast, patients with higher BMI were protected from attrition (≥30 vs 18.5--24.9 kg/m^2^, aHR: 0.57; 95% CI: 0.33--0.96).

Additionally, when looking specifically at LTFU by 12 months on treatment, no significant effects were observed across regimen types (FDC vs multi-pill, aHR: 1.02; 95% CI: 0.76--1.36) ([Table S1](#SD1-clep-10-017){ref-type="supplementary-material"}). Similarly, no significant effects across regimen types were noted for all-cause mortality by the same time point (FDC vs multi-pill, aHR: 0.97; 95% CI: 0.65--1.45) ([Table S2](#SD2-clep-10-017){ref-type="supplementary-material"}).

Missed medical visits by 12 months on ART
-----------------------------------------

[Table 3](#t3-clep-10-017){ref-type="table"} shows the crude RR and adjusted RR (aRR) estimates of missed medical visits by 12 months on ART. At this time point, a smaller proportion of those taking FDCs (11.3%) missed at least one medical visit compared to those taking multiple pills (17.5%). Similarly, in adjusted analyses, patients initiated on a FDC had a lower risk of missing at least one medical visit (aRR: 0.66; 95% CI: 0.52--0.83). Compared to their female counterparts, males were \~30% more likely to miss visits (aRR: 1.31; 95% CI: 1.07--1.60). The risk of missing visits in the first 12 months on treatment reduced with increasing age as older patients were less likely to miss at least one medical visit (≥55 vs 18--24, aRR: 0.42; 95% CI: 0.21--0.83).

When looking specifically at ARV pick-up visits during the first 12 months on treatment, a similar protective effect of FDCs in missing visits was observed (aRR: 0.57; 95% CI: 0.47--0.70) ([Table S3](#SD3-clep-10-017){ref-type="supplementary-material"}).

Viral load suppression at 6 and 12 months
-----------------------------------------

[Table 4](#t4-clep-10-017){ref-type="table"} shows the crude and aRR estimates of viral load suppression at 6 and 12 months post-ART initiation. At 6 months, 70% (647/921) of those who initiated FDC treatment vs 66% (1465/2230) of the multi-pill group had viral load tests. At this time point, virologic suppression was marginally higher among those taking FDCs (83 vs 77%; aRR: 1.10; 95% CI: 0.99--1.23). While not significant in the multivariate analysis, compared to females, males were less likely to achieve virologic suppression earlier in treatment (75.1 vs 80.8%; aRR: 0.93; 95% CI: 0.84--1.04). In relation to age group, older patients were more likely to have suppressed their viral load by 6 months on treatment (≥55 vs 18--24, aRR: 1.16; 95% CI: 0.85--1.59). Additionally, patients with lower CD4 cell counts were less likely to have suppressed viral loads at this time (0--50 vs ≥201, aRR: 0.90; 95% CI: 0.77--1.05), (51--100 vs ≥201, aRR: 0.89; 95% CI: 0.75--1.06), and (101--200 vs ≥201, aRR: 0.93; 95% CI: 0.82--1.06).

At 12 months, 31% (220/717) of those taking FDCs vs 33% (553/1657) of those taking multiple pills had viral load tests. Similar to viral load suppression at 6 months, patients on a FDC were marginally more likely to achieve viral suppression by 12 months on treatment (aRR: 1.12; 95% CI: 0.92--1.36). Young and middle-aged patients were less likely to suppress at this time point (25--34 vs 18--24, aRR: 0.93; 95% CI: 0.59--1.47) and (35--54 vs 18--24, aRR: 0.92; 95% CI: 0.59--1.43), respectively. As observed in the first 6 months, by 12 months patients with lower CD4 cell counts were also less likely to have suppressed their viral load (0--50 vs ≥201, aRR: 0.88; 95% CI: 0.68--1.14), (51--100 vs ≥201, aRR: 0.83; 95% CI: 0.60--1.14), and (101--200 vs ≥201, aRR: 0.90; 95% CI: 0.73--1.12)

Sensitivity analyses revealed a significant difference in suppression at 6 months among patients on a FDC, missing viral loads categorized as "suppressed", aRR: 1.07; 95% CI: 0.97--1.18 vs "unsuppressed", aRR: 1.15; 95% CI: 1.03--1.28 ([Table S4](#SD4-clep-10-017){ref-type="supplementary-material"}). However, no difference was observed by 12 months, missing viral loads categorized as "suppressed", aRR: 1.04; 95% CI: 0.94--1.15 vs "unsuppressed", aRR: 1.01; 95% CI: 0.83--1.23.

Discussion
==========

Currently, there are a limited number of studies focusing specifically on the effects of active ARV drugs administered as separate pills compared to those same active drugs administered in a FDC.[@b9-clep-10-017] Thus, the current study helps fill a critical gap in literature. In this study, we followed two groups of patients initiated on either a multi-pill or FDC regimen and assessed treatment outcomes 12 months post-ART initiation.

While the crude rate of attrition was somewhat lower among patients on a FDC, adjusted analyses revealed no significant differences in the risk of this outcome across regimen types 12 months post-ART initiation. Thereafter, compared to traditional multi-pill regimens, FDCs may not have a noticeable effect on patients' ability to remain alive and in care during the first 12 months of treatment. This early phase of treatment may be considered important as the behavioral challenges associated with starting a life-long treatment program are assumed to be at their highest. While adverse drug reactions (ADRs), treatment tolerability, clinic attendance, development of coinfections, concomitant treatments, and treatment/pill fatigue have been identified as barriers to adherence, cumulative time on treatment has also been associated with decreases in adherence levels.[@b5-clep-10-017],[@b6-clep-10-017],[@b9-clep-10-017],[@b24-clep-10-017]--[@b26-clep-10-017] It is at this time, later on in treatment, where a simplified, single-pill per day regimen may be more effective than a multi-pill regimen (each with varying dosing instructions serving to increase patient burden). Conversely, a FDC may be restrictive in its ability to form part of a holistic treatment plan which addresses coinfections. Limitations in single-drug substitutions may limit the use of FDCs later on in treatment, either periodically, when substitutions are needed, or more permanently.

As with attrition, there were no significant differences in the risk of virologic suppression among patients on a FDC compared to those on multi-pills. This was observed at both 6 and 12 months where patients on a FDC presented marginally higher rates of suppression with no discernible differences in risk (FDCs: 10 and 12% more likely to suppress at 6 and 12 months, respectively). Although numerous studies and randomized controlled trials (RCTs) evaluating the effects of FDCs (either partial or full) on virologic suppression (varying definitions/thresholds and durations of follow-up) have documented higher rates of suppression among patients on FDCs compared to those on multi-pill regimens,[@b27-clep-10-017] many of these studies examined virologic suppression across two non-identical regimens or among treatment-experienced patients, including those who switched to a FDC after initiating multi-pill therapy. Therefore, among treatment-naïve patients, comparing regimens similar in structure and dose in routine clinical care, the effects of pill number may not be a strong indication/predictor of virologic suppression.

During the study period (throughout enrolment of the multi-pill and FDC cohorts), improvements in adherence counseling and tracing initiatives among other interventions may have facilitated increasing levels of adherence and declining rates of LTFU. Specifically, during the enrolment of the FDC cohort, an automated pharmacy dispensing system was introduced at the study site. Although the impact of this system on patient treatment outcomes was not directly assessed, patient waiting times during medication collection were noticeably reduced. This may have contributed specifically to the reduction in missed ARV visits among patients on a FDC regimen ([Table S3](#SD3-clep-10-017){ref-type="supplementary-material"}). However, even when looking specifically at missed medical visits in the first 12 months of treatment, compared to the multi-pill cohort, patients on a FDC were 30% less likely to miss this type of visit. While the direct mechanism/s through which a reduced pill count may facilitate improved clinical/medical visit attendance need to be further explored, the benefits of increased monitoring among FDC patients may in turn lead to improved treatment outcomes later on in treatment.

Although focusing on more direct and indirect measures (pill counts, self-report) of adherence rather than proxy measures (missed visits), numerous studies have documented increases in adherence associated with FDCs.[@b12-clep-10-017],[@b28-clep-10-017],[@b29-clep-10-017] Additionally, randomized trials have also documented the benefits of FDCs in adherence to ART including improvements in correct dosing and timing.[@b30-clep-10-017]

Therefore, reduced pill counts and simplified pill taking, which improve treatment adherence, may ensure prolonged first-line treatment as well as prevent treatment failure and switching to more expensive and potentially limited second- and third-line regimens in the future.

Limitations
===========

Previous studies focusing on ART medication simplification tend to report adherence levels as a primary outcome. These often include self-report measures and unannounced pill counts. Unfortunately, these data are not routinely collected at the treatment site and could not be included as a potential outcome. We use missed medical visits as a proxy of adherence and are unable to provide a robust and reliable measure of this outcome. Follow-up studies examining the effects of FDCs on more direct adherence measures as well as the mechanisms through which a reduced pill count may improve clinic attendance are needed. Additionally, we were unable to comment on patient preferences, experiences, and quality of life with regard to regimen type. However, accurate measurements of treatment outcomes may serve as a strong indicator of the effects of FDCs.

While we were unable to compare the outcomes of patients on regimens with identical active drugs (TDF/FTC/EFV \[3--5 pills per day\] vs TDF/FTC/EFV \[1 pill per day\]),[@b10-clep-10-017] the documented interchangeability of FTC and 3TC assures the clinical validity of reported outcomes.[@b13-clep-10-017] In turn, this ensures that the observed effects may be attributed to the difference in pill count and dosing instructions opposed to significant variation of active agents across respective regimen types (multi-pill vs FDC).

Patients enrolled in the FDC and multi-pill cohorts were enrolled in two mutually exclusive time periods. This aspect of the study design was a function of the national treatment guideline changes between the study time periods and ensured two distinct treatment groups. While the non-overlapping nature of our respective cohorts may allow direct regimen comparisons, it may create confounding through changes or improvements in programmatic conditions between time periods. Programmatic changes (e.g., tracing initiatives, automated pharmacy dispensing, etc.) could have potentially impacted treatment outcomes investigated here.

Lastly, in this study, we were only able to observe treatment outcomes within the first 12 months of ART initiation. Critical to treatment success, adherence is a fluid process, influenced by a multitude of factors including socioeconomic status, health and treatment-related elements as well as behavioral tendencies.[@b31-clep-10-017],[@b32-clep-10-017] Consequently, a larger cohort with longer follow-up time is needed to identify longer-term outcomes which may differ from the initial effects of treatment initiation up to 1 year on treatment.

Conclusion
==========

FDC ART may be seen as a major advancement in the treatment of HIV-positive individuals. At the center of this simplified regimen is the facilitation of a reduced pill burden which has documented far reaching impacts, not only on clinical treatment outcomes but also on patient-centered outcomes such as quality of life. While the findings from this study may not, for the most part, illustrate these well-documented positive impacts of FDCs on HIV treatment outcomes identified in current literature, it is one of the first studies in Africa, particularly South Africa, which effectively examines the difference in outcomes between patients initiated on a single tablet first-line ART regimen compared to patients on a similar regimen administered as multiple drugs. We find that under programmatic conditions, FDCs do not significantly decrease rates of attrition or support noteworthy increases in virologic suppression compared to a multi-pill regimen. At the very least, these outcomes are similar regardless of the regimen type. However, FDCs may have a role to play in supporting patient adherence and monitoring through improved clinic attendance via medical visits. We find patients initiating ART on a FDC to be significantly less likely to miss medical visits in the first 12 months on treatment.

Supplementary materials
=======================

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on lost to follow-up

  Variable                                     n (%)              Lost to follow-up by 12 months (n=374/3151)   
  -------------------------------------------- ------------------ --------------------------------------------- -------------------
  Regimen                                                                                                       
   Multi-pill                                  286/2230 (12.8%)   1.00                                          1.00
   FDC                                         88/921 (9.6%)      0.74 (0.58--0.93)                             1.02 (0.76--1.36)
  Sex                                                                                                           
   Female                                      198/1863 (10.6%)   1.00                                          1.00
   Male                                        176/1288 (13.7%)   1.34 (1.10--1.64)                             1.24 (0.92--1.67)
  Age at initiation (years)                                                                                     
   18--24                                      29/159 (18.2%)     1.00                                          1.00
   25--34                                      137/1045 (13.1%)   0.69 (0.46--1.04)                             0.70 (0.40--1.22)
   35--54                                      184/1766 (10.4%)   0.55 (0.37--0.81)                             0.52 (0.30--0.90)
   ≥55                                         24/181 (13.3%)     0.76 (0.44--1.30)                             0.40 (0.16--0.98)
  CD4 cell count at initiation (cells/mm^3^)                                                                    
   0--50                                       70/528 (13.3%)     1.94 (1.42--2.65)                             1.52 (1.04--2.23)
   51--100                                     33/316 (10.4%)     1.40 (0.94--2.09)                             1.10 (0.68--1.78)
   101--200                                    69/669 (10.3%)     1.28 (0.94--1.76)                             1.10 (0.77--1.57)
   ≥201                                        89/1079 (8.2%)     1.00                                          1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                                       
   None                                        97/1026 (9.5%)     1.00                                          1.00
   Mild                                        94/1018 (9.2%)     1.01 (0.76--1.34)                             0.97 (0.70--1.36)
   Moderate                                    60/471 (12.7%)     1.58 (1.15--2.19)                             1.06 (0.68--1.65)
   Severe                                      45/178 (25.3%)     3.52 (2.47--5.02)                             2.36 (1.40--4.00)
  BMI at initiation (kg/m^2^)                                                                                   
   \<18.5                                      44/361 (12.2%)     1.29 (0.92--1.80)                             1.15 (0.79--1.68)
   18.5--24.9                                  147/1405 (10.5%)   1.00                                          1.00
   25--29.9                                    45/551 (8.2%)      0.75 (0.53--1.04)                             0.90 (0.62--1.31)
   ≥30                                         13/306 (4.3%)      0.38 (0.21--0.66)                             0.52 (0.28--0.97)
  WHO stage at initiation                                                                                       
   I and II                                    266/2523 (10.5%)   1.00                                          1.00
   III and IV                                  108/628 (17.2%)    1.85 (1.48--2.32)                             0.87 (0.60--1.26)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, anemia, BMI, and WHO stage;

adjusted hazard ratio of lost to follow-up by 12 months (n=208/2226)

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; HR, hazard ratio; BMI, body mass index; WHO, World Health Organization.

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on all-cause mortality

  Variable                                     n (%)             All-cause mortality by 12 months (n=178/3151)   
  -------------------------------------------- ----------------- ----------------------------------------------- --------------------
  Regimen                                                                                                        
   Multi-pill                                  125/2230 (5.6%)   1.00                                            1.00
   FDC                                         53/921 (5.8%)     1.02 (0.74--1.41)                               0.97 (0.65--1.45)
  Sex                                                                                                            
   Female                                      88/1863 (4.7%)    1.00                                            1.00
   Male                                        90/1288 (7.0%)    1.51 (1.13--2.03)                               1.54 (1.03--2.32)
  Age at initiation (years)                                                                                      
   18--24                                      1/159 (0.6%)      1.00                                            1.00
   25--34                                      48/1045 (4.6%)    7.23 (1.00--52.36)                              2.52 (0.34--18.64)
   35--54                                      111/1766 (6.3%)   9.93 (1.39--71.09)                              3.66 (0.50--26.52)
   ≥55                                         18/181 (9.9%)     16.29 (2.18--122.02)                            6.45 (0.82--50.59)
  CD4 cell count at initiation (cells/mm^3^)                                                                     
   0--50                                       72/528 (13.6%)    9.11 (5.43--15.27)                              8.19 (4.29--15.65)
   51--100                                     25/316 (7.9%)     5.02 (2.74--9.14)                               4.69 (2.25--9.77)
   101--200                                    22/669 (3.3%)     2.00 (1.07--3.73)                               2.25 (1.09--4.66)
   ≥201                                        18/1079 (1.7%)    1.00                                            1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                                        
   None                                        21/1026 (2.1%)    1.00                                            --
   Mild                                        51/1018 (5.0%)    2.49 (1.50--4.14)                               --
   Moderate                                    57/471 (12.1%)    6.45 (3.91--10.64)                              --
   Severe                                      23/178 (12.9%)    7.21 (4.00--13.04)                              --
  BMI at initiation (kg/m^2^)                                                                                    
   \<18.5                                      43/361 (11.9%)    3.10 (2.09--4.61)                               2.15 (1.39--3.32)
   18.5--24.9                                  57/1405 (4.1%)    1.00                                            1.00
   25--29.9                                    16/551 (2.9%)     0.70 (0.40--1.21)                               1.03 (0.57--1.85)
   ≥30                                         5/306 (1.6%)      0.39 (0.16--0.97)                               0.58 (0.20--1.65)
  WHO stage at initiation                                                                                        
   I and II                                    111/2523 (4.4%)   1.00                                            1.00
   III and IV                                  67/628 (10.7%)    2.59 (1.91--3.51)                               1.15 (0.75--1.76)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, BMI, and WHO stage;

adjusted hazard ratio of all-cause mortality by 12 months (n=106/2304).

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; HR, hazard ratio; BMI, body mass index; WHO, World Health Organization.

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on missed ARV visits (≥1)

  Variable                                     n (%)              Missed ARV visits by 12 months (n=715/3061)   
  -------------------------------------------- ------------------ --------------------------------------------- -------------------
  Regimen                                                                                                       
   Multi-pill                                  573/2143 (26.7%)   1.00                                          1.00
   FDC                                         142/918 (15.5%)    0.58 (0.48--0.70)                             0.57 (0.47--0.70)
  Sex                                                                                                           
   Female                                      404/1816 (22.3%)   1.00                                          1.00
   Male                                        311/1245 (25.0%)   1.12 (0.97--1.30)                             1.21 (1.03--1.43)
  Age at initiation (years)                                                                                     
   18--24                                      35/151 (23.2%)     1.00                                          1.00
   25--34                                      264/1013 (26.1%)   1.12 (0.79--1.60)                             1.18 (0.78--1.78)
   35--54                                      382/1722 (22.2%)   0.96 (0.68--1.35)                             1.01 (0.67--1.52)
   ≥55                                         34/175 (19.4%)     0.84 (0.52--1.34)                             0.87 (0.51--1.49)
  CD4 cell count at initiation (cells/mm^3^)                                                                    
   0--50                                       109/515 (21.2%)    0.94 (0.75--1.17)                             0.93 (0.74--1.18)
   51--100                                     79/310 (25.5%)     1.13 (0.87--1.45)                             1.11 (0.85--1.43)
   101--200                                    173/654 (26.5%)    1.17 (0.96--1.42)                             1.17 (0.96--1.42)
   ≥201                                        240/1061 (22.6%)   1.00                                          1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                                       
   None                                        240/1023 (23.5%)   1.00                                          --
   Mild                                        231/1013 (22.8%)   0.97 (0.81--1.16)                             --
   Moderate                                    101/465 (21.7%)    0.93 (0.73--1.17)                             --
   Severe                                      45/171 (26.3%)     1.12 (0.82--1.54)                             --
  BMI at initiation (kg/m^2^)                                                                                   
   \<18.5                                      73/359 (20.3%)     0.81 (0.63--1.05)                             --
   18.5--24.9                                  350/1400 (25.0%)   1.00                                          --
   25--29.9                                    124/549 (22.6%)    0.90 (0.74--1.11)                             --
   ≥30                                         71/306 (23.2%)     0.93 (0.72--1.20)                             --
  WHO stage at initiation                                                                                       
   I and II                                    572/2448 (23.4%)   1.00                                          1.00
   III and IV                                  143/613 (23.3%)    1.00 (0.83--1.20)                             1.07 (0.87--1.32)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, and WHO stage;

adjusted relative rate of missed ARV visits by 12 months (n=601/2540).

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; ARV, antiretroviral; RR, relative rate; BMI, body mass index; WHO, World Health Organization.

###### 

Virological suppression sensitivity analysis

  0--12 month outcomes                                                                      n (%)                                                           Adjusted RR[a](#tfn21-clep-10-017){ref-type="table-fn"} (95% CI)
  ----------------------------------------------------------------- ----------------------- --------------------------------------------------------------- ------------------------------------------------------------------
  Virologic suppression at 6 months -- missing data suppressed      Multi-pill initiation   1525/1868 (81.6%)                                               1.00
  FDC initiation                                                    676/787 (85.9%)         1.07 (0.97--1.18)[b](#tfn22-clep-10-017){ref-type="table-fn"}   
  Virologic suppression at 6 months -- missing data unsuppressed    Multi-pill initiation   1122/1868 (60.1%)                                               1.00
  FDC initiation                                                    536/787 (68.1%)         1.15 (1.03--1.28)[c](#tfn23-clep-10-017){ref-type="table-fn"}   
  Virologic suppression at 12 months -- missing data suppressed     Multi-pill initiation   1518/1667 (91.1%)                                               1.00
  FDC initiation                                                    680/719 (94.6%)         1.04 (0.94--1.15)[d](#tfn24-clep-10-017){ref-type="table-fn"}   
  Virologic suppression at 12 months -- missing data unsuppressed   Multi-pill initiation   404/1667 (24.2%)                                                1.00
  FDC initiation                                                    181/719 (25.2%)         1.01 (0.83--1.23)[e](#tfn25-clep-10-017){ref-type="table-fn"}   

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, and WHO stage;

adjusted relative rate of viral load suppression by 6 months (missing data as suppressed) (n=1857/2245);

adjusted relative rate of viral load suppression by 6 months (missing data as unsuppressed) (n=1440/2245);

adjusted relative rate of viral load suppression by 6 months (missing data as suppressed) (n=1880/2033);

adjusted relative rate of viral load suppression by 6 months (missing data as unsuppressed) (n=498/2033).

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; RR, relative rate; WHO, World Health Organization.
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###### 

Multi-pill vs fixed-dose combination therapy by demographic and clinical characteristics at ART initiation

  Variable                                                          Multi-pill initiation (n=2230)   FDC initiation (n=921)   Total (N=3151) n (%)
  --------------------------------------------- ------------------- -------------------------------- ------------------------ -----------------------
  Sex                                           Female              1363/2230 (61.1%)                500/921 (54.3%)          1863/3151 (59.1%)
  Male                                          867/2230 (38.9%)    421/921 (45.7%)                  1288/3151 (40.9%)        
  Missing                                       0                   0                                0                        
  Age at initiation (years)                     Median (IQR)        37.8 (31.7--45.0)                37.8 (31.8--45.0)        37.8 (31.7--45.0)
  18--24                                        112/2230 (5.0%)     47/921 (5.1%)                    159/3151 (5.0%)          
  25--34                                        745/2230 (33.4%)    300/921 (32.6%)                  1045/3151 (33.2%)        
  35--54                                        1241/2230 (55.7%)   525/921 (57.0%)                  1766/3151 (56.1%)        
  ≥55                                           132/2230 (5.9%)     49/921 (5.3%)                    181/3151 (5.7%)          
  Missing                                       0                   0                                0                        
  CD4 cell count at initiation (cells/mm^3^)    Median (IQR)        175.5 (76.5--268.0)              158.0 (52.0--282.5)      171.0 (70.0--272.5--)
  0--50                                         338/1820 (18.6%)    190/772 (24.6%)                  528/2592 (20.4%)         
  51--100                                       224/1820 (12.3%)    92/772 (11.9%)                   316/2592 (12.2%)         
  101--200                                      476/1820 (26.2%)    193/772 (25.0%)                  669/2592 (25.8%)         
  201--350                                      703/1820 (38.6%)    214/772 (27.7%)                  917/2592 (35.4%)         
  \>350                                         79/1820 (4.3%)      83/772 (10.8%)                   162/2592 (6.3%)          
  Missing                                       410                 149                              559                      
  Hemoglobin at initiation, g/dL (anemia)       Median (IQR)        11.7 (10.1--13.1)                11.9 (10.2--13.2)        11.8 (10.1--13.1)
  None                                          678/1809 (37.5%)    348/884 (39.4%)                  1026/2693 (38.1%)        
  Mild                                          681/1809 (37.7%)    337/884 (38.1%)                  1018/2693 (37.8%)        
  Moderate                                      315/1809 (17.4%)    156/884 (17.7%)                  471/2693 (17.5%)         
  Severe                                        135/1809 (7.5%)     43/884 (4.9%)                    178/2693 (6.6%)          
  Missing                                       421                 37                               458                      
  Creatinine clearance at initiation (mL/min)   Median (IQR)        107.7 (91.2--125.6)              104.5 (89.3--123.2)      107.0 (90.4--124.9)
  Normal                                        1308/1784 (73.3%)   494/709 (69.7%)                  1802/2493 (72.3%)        
  Low                                           476/1784 (26.7%)    215/709 (30.3%)                  691/2493 (27.7%)         
  Missing                                       446                 212                              658                      
  WHO stage at initiation                       I                   1644/2230 (73.7%)                635/921 (69.0%)          2279/3151 (72.3%)
  II                                            138/2230 (6.2%)     106/921 (11.5%)                  244/3151 (7.7%)          
  III                                           222/2230 (10.0%)    95/921 (10.3%)                   317/3151 (10.1%)         
  IV                                            226/2230 (10.1%)    85/921 (9.2%)                    311/3151 (9.9%)          
  Missing                                       0                   0                                0                        
  BMI at initiation (kg/m^2^)                   Median (IQR)        22.7 (19.9--26.5)                22.4 (19.7--25.8)        22.6 (19.8--26.2)
  \<18.5                                        240/1761 (13.6%)    121/862 (14.0%)                  361/2623 (13.8%)         
  18.5--24.9                                    925/1761 (52.5%)    480/862 (55.7%)                  1405/2623 (53.6%)        
  25--29.9                                      379/1761 (21.5%)    172/862 (20.0%)                  551/2623 (21.0%)         
  ≥30                                           217/1761 (12.3%)    89/862 (10.3%)                   306/2623 (11.7%)         
  Missing                                       469                 59                               528                      
  Total follow-up time (months)                 Median (IQR)        48.2 (11.5--51.7)                23.1 (19.5--27.1)        43.9 (19.3--50.0)
                                                                                                                              
  **By 12 months on ART**                                                                                                     
                                                                                                                              
  Treatment outcomes                            Alive in care       1657/2230 (74.3%)                717/921 (77.9%)          2374/3151 (75.3%)
  Lost to follow-up                             286/2230 (12.8%)    88/921 (9.6%)                    374/3151 (11.9%)         
  Dead                                          125/2230 (5.6%)     53/921 (5.8%)                    178/3151 (5.6%)          
  Transferred out                               162/2230 (7.3%)     63/921 (6.8%)                    225/3151 (7.1%)          
  Missing                                       0                   0                                0                        
  Missed medical visits                         0                   1735/2102 (82.5%)                810/913 (88.7%)          2545/3015 (84.4%)
  1                                             303/2102 (14.4%)    88/913 (9.6%)                    391/3015 (13.0%)         
  2                                             55/2102 (2.6%)      15/913 (1.6%)                    70/3015 (2.3%)           
  ≥3                                            9/2102 (0.4%)       0 (0.0%)                         9/3015 (0.3%)            
  Missing                                       128                 8                                136                      
  Viral suppression                             6 months            1122/1465 (76.6%)                536/647 (82.8%)          1658/2112 (78.5%)
  Missing                                       765                 274                              1039                     
  Viral suppression                             12 months           404/553 (73.1%)                  181/220 (82.3%)          585/773 (75.7%)
  Missing                                       1104                497                              1601                     

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; IQR, interquartile range; BMI, body mass index; WHO, World Health Organization.

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on attrition (LTFU + all-cause mortality)

  Variable                                     n (%)              Attrition by 12 months (n=552/3151)   
  -------------------------------------------- ------------------ ------------------------------------- -------------------
  Regimen                                                                                               
   Multi-pill                                  411/2230 (18.4%)   1.00                                  1.00
   FDC                                         141/921 (15.3%)    0.82 (0.68--1.00)                     0.98 (0.77--1.24)
  Sex                                                                                                   
   Female                                      286/1863 (15.4%)   1.00                                  1.00
   Male                                        266/1288 (20.7%)   1.39 (1.18--1.64)                     1.49 (1.17--1.90)
  Age at initiation (years)                                                                             
   18--24                                      30/159 (18.9%)     1.00                                  1.00
   25--34                                      185/1045 (17.7%)   0.91 (0.62--1.34)                     0.78 (0.46--1.33)
   35--54                                      295/1766 (16.7%)   0.86 (0.59--1.25)                     0.72 (0.43--1.22)
   ≥55                                         42/181 (23.2%)     1.28 (0.80--2.04)                     0.80 (0.40--1.61)
  CD4 cell count at initiation (cells/mm^3^)                                                            
   0--50                                       142/528 (26.9%)    3.18 (2.47--4.09)                     2.29 (1.69--3.12)
   51--100                                     58/316 (18.4%)     2.02 (1.47--2.78)                     1.48 (1.01--2.16)
   101--200                                    91/669 (13.6%)     1.40 (1.06--1.85)                     1.20 (0.87--1.64)
   ≥201                                        107/1079 (9.9%)    1.00                                  1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                               
   None                                        118/1026 (11.5%)   1.00                                  1.00
   Mild                                        145/1018 (14.2%)   1.27 (1.00--1.62)                     1.07 (0.80--1.43)
   Moderate                                    117/471 (24.8%)    2.48 (1.92--3.20)                     1.71 (1.22--2.39)
   Severe                                      68/178 (38.2%)     4.17 (3.09--5.61)                     2.42 (1.56--3.75)
  BMI at initiation (kg/m^2^)                                                                           
   \<18.5                                      87/361 (24.1%)     1.81 (1.40--2.32)                     1.42 (1.07--1.87)
   18.5--24.9                                  204/1405 (14.5%)   1.00                                  1.00
   25--29.9                                    61/551 (11.1%)     0.73 (0.55--0.98)                     0.96 (0.70--1.32)
   ≥30                                         18/306 (5.9%)      0.38 (0.24--0.62)                     0.57 (0.33--0.96)
  WHO stage at initiation                                                                               
   I and II                                    377/2523 (14.9%)   1.00                                  1.00
   III and IV                                  175/628 (27.9%)    2.08 (1.74--2.48)                     0.90 (0.68--1.19)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, anemia, BMI, and WHO stage;

adjusted hazard ratio of attrition by 12 months (n=312/2226)

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; LTFU, lost to follow-up; HR, hazard ratio; BMI, body mass index; WHO, World Health Organization.

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on missed medical visits (≥1)

  Variable                                     n (%)              Missed medical visits by 12 months (n=470/3015)   
  -------------------------------------------- ------------------ ------------------------------------------------- -------------------
  Regimen                                                                                                           
   Multi-pill                                  367/2102 (17.5%)   1.00                                              1.00
   FDC                                         103/913 (11.3%)    0.65 (0.52--0.80)                                 0.66 (0.52--0.83)
  Sex                                                                                                               
   Female                                      258/1790 (14.4%)   1.00                                              1.00
   Male                                        212/1225 (17.3%)   1.20 (1.00--1.44)                                 1.31 (1.07--1.60)
  Age at initiation (years)                                                                                         
   18--24                                      30/148 (20.3%)     1.00                                              1.00
   25--34                                      167/995 (16.8%)    0.83 (0.56--1.22)                                 0.78 (0.50--1.21)
   35--54                                      255/1702 (15.0%)   0.74-0.51--1.08)                                  0.71 (0.46--1.09)
   ≥55                                         18/170 (10.6%)     0.52 (0.29--0.94)                                 0.42 (0.21--0.83)
  CD4 cell count at initiation (cells/mm^3^)                                                                        
   0--50                                       84/503 (16.7%)     1.15 (0.88--1.50)                                 1.08 (0.82--1.43)
   51--100                                     46/306 (15.0%)     1.04 (0.74--1.44)                                 1.00 (0.72--1.40)
   101--200                                    111/648 (17.1%)    1.18 (0.92--1.51)                                 1.17 (0.91--1.49)
   ≥201                                        153/1054 (14.5%)   1.00                                              1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                                           
   None                                        148/1014 (14.6%)   1.00                                              --
   Mild                                        144/1007 (14.3%)   0.98 (0.78--1.23)                                 --
   Moderate                                    72/450 (16.0%)     1.10 (0.83--1.45)                                 --
   Severe                                      34/165 (20.6%)     1.41 (0.97--2.05)                                 --
  BMI at initiation (kg/m^2^)                                                                                       
   \<18.5                                      53/357 (14.9%)     0.91 (0.67--1.23)                                 --
   18.5--24.9                                  228/1396 (16.3%)   1.00                                              --
   25--29.9                                    83/550 (15.1%)     0.92 (0.72--1.19)                                 --
   ≥30                                         31/305 (10.2%)     0.62 (0.43--0.91)                                 --
  WHO stage at initiation                                                                                           
   I and II                                    364/2422 (15.0%)   1.00                                              1.00
   III and IV                                  106/593 (17.9%)    1.19 (0.96--1.48)                                 1.26 (0.98--1.61)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, and WHO stage;

adjusted relative rate of missed medical visits by 12 months (n=394/2511)

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; RR, relative rate; BMI, body mass index; WHO, World Health Organization.

###### 

Unadjusted and adjusted estimates of the relation between multi-pill initiation and fixed-dose combination initiation on virological suppression

  Variable                                     n (%)               VL suppression at 6 months (n=1658/2112)   n (%)               VL suppression at 12 months (n=585/773)                       
  -------------------------------------------- ------------------- ------------------------------------------ ------------------- ----------------------------------------- ------------------- -------------------
  Regimen                                                                                                                                                                                       
   Multi-pill                                  1122/1465 (76.6%)   1.00                                       1.00                404/553 (73.1%)                           1.00                1.00
   FDC                                         536/647 (82.8%)     1.08 (0.98--1.20)                          1.10 (0.99--1.23)   181/220 (82.3%)                           1.13 (0.95--1.34)   1.12 (0.92--1.36)
  Sex                                                                                                                                                                                           
   Female                                      1029/1274 (80.8%)   1.00                                       1.00                359/466 (77.0%)                           1.00                1.00
   Male                                        629/838 (75.1%)     0.93 (0.84--1.03)                          0.93 (0.84--1.04)   226/307 (73.6%)                           0.96 (0.81--1.13)   0.97 (0.80--1.16)
  Age at initiation (years)                                                                                                                                                                     
   18--24                                      77/94 (81.9%)       1.00                                       1.00                25/30 (83.3%)                             1.00                1.00
   25--34                                      539/696 (77.4%)     0.95 (0.74--1.20)                          0.97 (0.74--1.25)   187/246 (76.0%)                           0.91 (0.60--1.38)   0.93 (0.59--1.47)
   35--54                                      934/1207 (77.4%)    0.94 (0.75--1.19)                          0.97 (0.75--1.25)   351/471 (74.5%)                           0.89 (0.60--1.34)   0.92 (0.59--1.43)
   ≥55                                         108/115 (93.9%)     1.15 (0.86--1.54)                          1.16 (0.85--1.59)   22/26 (84.6%)                             1.02 (0.57--1.80)   1.00 (0.53--1.88)
  CD4 cell count at initiation (cells/mm^3^)                                                                                                                                                    
                                                                                                                                                                                                
   0--−50                                      240/320 (75.0%)     0.91 (0.78--1.05)                          0.90 (0.77--1.05)   90/125 (72.0%)                            0.87 (0.68--1.12)   0.88 (0.68--1.14)
   51--100                                     163/222 (73.4%)     0.89 (0.75--1.05)                          0.89 (0.75--1.06)   45/67 (67.2%)                             0.82 (0.59--1.12)   0.83 (0.60--1.14)
   101--200                                    380/491 (77.4%)     0.94 (0.83--1.06)                          0.93 (0.82--1.06)   134/181 (74.0%)                           0.90 (0.73--1.11)   0.90 (0.73--1.12)
   ≥201                                        657/795 (82.6%)     1.00                                       1.00                229/278 (82.4%)                           1.00                1.00
  Hemoglobin at initiation, g/dL (Anemia)                                                                                                                                                       
   None                                        605/746 (81.1%)     1.00                                       --                  202/258 (78.3%)                           1.00                --
   Mild                                        590/760 (77.6%)     0.96 (0.85--1.07)                          --                  196/262 (74.8%)                           0.96 (0.79--1.16)   --
   Moderate                                    220/292 (75.3%)     0.93 (0.80--1.08)                          --                  76/107 (71.0%)                            0.91 (0.70--1.18)   --
   Severe                                      64/84 (76.2%)       0.94 (0.73--1.22)                          --                  23/34 (67.7%)                             0.86 (0.56--1.33)   --
  BMI at initiation (kg/m^2^)                                                                                                                                                                   
   \<18.5                                      170/226 (75.2%)     0.97 (0.83--1.15)                          --                  55/78 (70.5%)                             0.95 (0.71--1.26)   --
   18.5--24.9                                  790/1023 (77.2%)    1.00                                       --                  275/369 (74.5%)                           1.00                --
   25--29.9                                    341/417 (81.8%)     1.06 (0.93--1.20)                          --                  120/153 (78.4%)                           1.05 (0.85--1.30)   --
   ≥30                                         201/240 (83.8%)     1.08 (0.93--1.27)                          --                  64/77 (83.1%)                             1.12 (0.85--1.46)   --
  WHO stage at initiation                                                                                                                                                                       
   I and II                                    1368/1735 (78.9%)   1.00                                       1.00                492/639 (77.0%)                           1.00                1.00
   III and IV                                  290/377 (76.9%)     0.98 (0.86--1.11)                          1.02 (0.88--1.17)   93/134 (69.4%)                            0.90 (0.72--1.13)   0.97 (0.76--1.24)

**Notes:**

Model adjusted for the following variables at ART initiation: regimen type, sex, age, CD4 cell count, and WHO stage;

adjusted relative rate of viral load suppression by 6 months (n=1440/1828);

adjusted relative rate of viral load suppression by 12 months (n=498/651).

**Abbreviations:** ART, antiretroviral therapy; FDC, fixed-dose combination; VL, viral load; RR, relative rate; BMI, body mass index; WHO, World Health Organization.
